• LAST PRICE
    0.9402
  • TODAY'S CHANGE (%)
    Trending Up0.0102 (1.0968%)
  • Bid / Lots
    0.9401/ 2
  • Ask / Lots
    0.9402/ 1
  • Open / Previous Close
    0.9550 / 0.9300
  • Day Range
    Low 0.9300
    High 0.9550
  • 52 Week Range
    Low 0.3899
    High 4.3940
  • Volume
    31,800
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.93
TimeVolumeTOVX
09:32 ET3950.955
09:39 ET6260.9401
09:48 ET4000.94945
09:50 ET18300.9491
09:51 ET1000.945
10:02 ET22780.94
10:04 ET2000.9498
10:06 ET18420.94
10:09 ET8000.9301
10:22 ET2000.937
10:26 ET1000.9338
11:03 ET10000.93495
11:18 ET9600.93
11:38 ET3000.9399
11:41 ET7590.93495
11:48 ET160000.9349
11:50 ET14960.94
11:52 ET3000.940001
11:54 ET1000.94505
11:59 ET2270.940101
12:03 ET1000.9401
12:08 ET3890.9402
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTOVX
Theriva Biologics Inc
14.7M
-0.7x
---
United StatesMOBO
Avail Scientific Inc
14.6M
-2.5x
---
United StatesNRBO
Neurobo Pharmaceuticals Inc
15.2M
-0.1x
---
United StatesGRAY
Graybug Vision Inc
15.3M
-0.4x
---
United StatesINDP
Indaptus Therapeutics Inc
14.0M
-1.0x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
15.7M
-0.7x
---
As of 2023-02-02

Company Information

Theriva Biologics, Inc., formerly Synthetic Biologics, Inc., is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of unmet need. The Company is engaged in the development of oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient's immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.

Contact Information

Headquarters
9605 Medical Center Drive, Suite 270ROCKVILLE, MD, United States 20850
Phone
734-332-7800
Fax
734-332-7878

Executives

Independent Chairman of the Board
Jeffrey Kraws
Chief Executive Officer, Chief Financial Officer, Director
Steven Shallcross
Chief Operating Officer
Frank Tufaro
Independent Director
John Monahan
Independent Director
Jeffrey Wolf

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.7M
Revenue (TTM)
$0.00
Shares Outstanding
15.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.57
EPS
$-1.35
Book Value
$4.95
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.